Sundar Kodiyalam is managing director of Vatera Holdings and a co-founder of Vatera Healthcare Partners. In addition to being a member of the board of directors of Melinta Therapeutics, he is a member of the boards of directors of Ekteino Laboratories Inc., ImmusanT, Inc., and Edgemont Pharmaceuticals LLC. Mr. Kodiyalam also previously served on the board of directors of Pearl Therapeutics until its sale to AstraZeneca.
Prior to Vatera, Mr. Kodiyalam worked as senior vice president, corporate development and new business opportunities at Kos Pharmaceuticals. During his four-year tenure at Kos, sales contributions from licensed products grew from zero to more than 25 percent as a result of transactions completed by Mr. Kodiyalam and his team. The company also boasted a robust late-stage pipeline partially built through successful licensing efforts. Mr. Kodiyalam was also a key member of the management team that worked on the sale of Kos Pharmaceuticals to Abbott Laboratories. Prior to Kos, Mr. Kodiyalam was vice president of commercial development at Ortec International, a tissue engineering company. Mr. Kodiyalam’s experience with big pharma includes three years at Schering-Plough as director of business development and licensing and 10 years at Novartis Pharmaceuticals in domestic and international marketing roles.
Mr. Kodiyalam earned his M.S. in pharmaceutical administration from Ohio State University and B.A. in pharmacy from Madras University, India.